Genetic disorder gets name change, but patient’s father still not happy

Credit: Online Mendelian Inheritance in Man

The leading genetic disease database has chosen a new name for a genetic condition, following complaints from a man whose son has the condition.

On Aug. 11, 2017, two days after our coverage of the situation, the Online Mendelian Inheritance in Man (OMIM) database changed the primary name of the phenotype associated with mutations in the RPS23 gene. The new name describes a set of features: “Brachycephaly, Trichomegaly, and Developmental Delay,” or BTDD.

Brachycephaly describes a condition where the back of the head is abnormally flat and trichomegaly refers to extra length, curling, pigmentation, or thickness of the eyelashes.

Marc Pieterse, of the Netherlands, has a son with the rare RPS23 mutation, one of two known patients in the world. The mutation affects ribosomes, cell components involved in protein production. On Aug. 9, we reported on Pieterse’s crusade against OMIM’s original name for the condition, which dubbed it a syndrome. He has feared that calling it a syndrome would “stigmatize” his son’s condition and tried to get the paper underpinning the OMIM entry retracted. The American Journal of Human Genetics has said it will not retract the paper.

Continue reading Genetic disorder gets name change, but patient’s father still not happy

“The paper is extremely flawed:” Journal retracts article linked to vaccines

A journal has retracted a 2016 paper after receiving criticism from outside researchers who raised concerns about its methodology and data.

The paper shares multiple authors with another paper that linked the vaccine for human papillomavirus (HPV) to behavioral problems in mice. Last year, a journal removed the study; later that year, the authors published a revised version in another journal. The latest retracted paper focuses on the antibodies present in a form of lupus.

Yehuda Shoenfeld at Tel-Aviv University in Israel, the corresponding author on both this latest retraction and the HPV vaccine paper, recently edited a textbook that explored how vaccines can induce autoimmunity in some people.  He told us the 2016 lupus paper does have a link to vaccines [his emphasis]:

Continue reading “The paper is extremely flawed:” Journal retracts article linked to vaccines

What should journals do when peer reviewers do not disclose potential conflicts?

Peer reviewers, like authors, are supposed to declare any potential conflicts of interest. But what happens when they don’t?

Take this case: In a court transcript from Feb. 23, 2017, Bryan Hardin testified that he was a peer reviewer on a 2016 paper in Critical Reviews in Toxicology, which found that asbestos does not increase the risk of cancer. In the deposition, Hardin—who works at the consulting firm Veritox—also said that he has testified in asbestos litigation on behalf of automakers, such as Ford, General Motors, and Chrysler, but said he had not disclosed these relationships to the journal.

Last year, the first author of the 2016 review withdrew a paper from another journal (by the same publisher) which concluded asbestos roofing products are safe, following several criticisms — including not disclosing the approving editor’s ties to the asbestos industry. In this latest case, the journal told us it believes the review process for the paper was up to snuff, but two outside experts we consulted said they believed Hardin’s relationships — and failure to disclose them — should give the journal pause.

We obtained a copy of the transcript from Christian Hartley, who was representing a man suing a mining company because the man developed cancer after being exposed to asbestos at work. When Hartley asked Hardin whether he had told the journal about testifying for companies involved in asbestos litigation, Hardin responded:

Continue reading What should journals do when peer reviewers do not disclose potential conflicts?

Journal corrects paper by researcher sanctioned for misconduct

A biology journal has issued a correction to a 2014 paper by a researcher with 11 retractions, citing “inadvertent errors” that don’t affect the conclusions.

The researcher, Rony Seger, was recently sanctioned by his institution (The Weizmann Institute in Israel) following a finding of “serious misconduct” involving data manipulation. Specifically, the institute barred him from supervising graduate students, even future ones; his lab is now dedicated to replicating his previous work, with the help of a technician.

Last month, Michal Neeman, vice president of The Weizmann Institute of Science, told us she wasn’t sure how many additional papers by Seger would need to be retracted or corrected.

Recently, one more was revealed — in the August issue of Molecular and Cellular Biology, the following correction notice appears:

Continue reading Journal corrects paper by researcher sanctioned for misconduct

Weekend reads: Predatory fraud; risky spreadsheets; how to report issues in a paper

The week at Retraction Watch featured a look at publishing bounties around the world, and the story of how the “right to be forgotten” law had led to a retraction. Here’s what was happening elsewhere: Continue reading Weekend reads: Predatory fraud; risky spreadsheets; how to report issues in a paper

JAMA tells readers: “Caution advised.” Here’s why.

Last week, JAMA issued some unusual notices, letting readers know they should use caution when reading an editorial and letters associated with now-retracted articles by a bone researcher in Japan.

The notices — for papers by Yoshihiro Sato, now up to 14 retractions — remind readers not to heed the results of the now-retracted papers, and alert them to read any associated materials (specifically, an editorial in JAMA and letters in JAMA Internal Medicine) with caution.

The text of the notices describes them as “formal correction notices;” we asked Annette Flanagin, executive managing editor at The JAMA Network, why they chose that approach, instead of an expression of concern or retraction:

Continue reading JAMA tells readers: “Caution advised.” Here’s why.

Scientist steps down from South Korea government position over criticism of her role in stem cell scandal

A professor at Sunchon National University has resigned from a prominent government position in South Korea after facing heavy criticism for being a co-author of a fraudulent stem cell paper.

Earlier this week, President Moon Jae-in appointed Park Ky-young to run a newly created Science, Technology and Innovation Office at the Ministry of Science and ICT. Critics quickly cried foul, noting that Park co-authored one of the stem cell papers by Woo-Suk Hwang, which made headlines 10 years ago after an investigation revealed the supposedly groundbreaking research had been fabricated.

According to the Korea Herald, Park’s position would have given her a say over the country’s R&D budget, worth 20 trillion won ($17 billion USD) in the science sector. The appointment does not require approval from parliament.

Today, Park agreed to step down. In a written statement, she said:

Continue reading Scientist steps down from South Korea government position over criticism of her role in stem cell scandal

Paid to publish: It’s not just China

A recent pre-print showed that scientists in China can earn up to $165,000 to publish a paper in a top journal, but that’s not the only place where researchers can get some extra cash.

Recently, we conducted an informal search for other institutions around the world that offer cash prizes for publishing research — and were surprised at what we found.

People have raised concerns about these incentives, given that they often just overload top journals with submissions, but don’t necessarily increase publication rates. Furthermore, there are concerns that these kinds of incentives can encourage fraudulent publishing practices — such as fake peer reviews — out of countries such as China.

Check out where else scientists can earn almost $14,000 USD per paper, as part of our latest feature in Science, out today.

Like Retraction Watch? Consider making a tax-deductible contribution to support our growth. You can also follow us on Twitter, like us on Facebook, add us to your RSS reader, sign up on our homepage for an email every time there’s a new post, or subscribe to our daily digest. Click here to review our Comments Policy. For a sneak peek at what we’re working on, click here.

Researcher who shot dean after being fired for misconduct sentenced to 28 years in prison

Hengjun Chao. Credit: Westchester County DA

A former researcher at Mount Sinai’s medical school has been sentenced to 28 years in prison for shooting the dean that fired him.

On the morning of Aug. 29, 2016, Chao, 50, attacked Dennis Charney, dean of the Icahn School of Medicine at Mount Sinai, with a shotgun outside a deli in suburban New York. In 2010, Charney fired Chao for scientific misconduct. Charney survived the shot, but was hospitalized for five days.

As reported by the Chappaqua-Mount Kisco Patch yesterday, Judge Barry Warhit sentenced Hengjun Chao to 23 years, each, for attempted murder and assault, to be served concurrently; the maximum sentence for the attempted murder charge that Chao faced was 25 years. The judge also sentenced Chao to the maximum for criminal use of a firearm — five years — which will be served consecutively, bringing the total to 28 years.

In June, a New York jury found him guilty of attempted murder and the two other felony charges.

Stewart Orden, Chao’s defense attorney, told Retraction Watch he was “shocked at the sentence:” Continue reading Researcher who shot dean after being fired for misconduct sentenced to 28 years in prison

Unearthed emails: Monsanto connected to campaign to retract GMO paper

A trove of internal documents from Monsanto, recently unsealed in a lawsuit against the agricultural biotech giant, has revealed the firm’s role in the knotty tale of a paper from the lab of a scientist known for his stance against genetically modified organisms (GMOs).

That paper is “Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize,” published in September 2012 in the journal Food and Chemical Toxicology (FCT) and retracted in January 2014. Gilles Seralini, a scientist known for an adversarial stance towards GMOs, was first author. The documents have also spurred the retraction of several pro-GMO articles on Forbes.com written by Henry Miller, a fellow at the Hoover Institution, a conservative think tank at Stanford University. Emails showed that one of the articles, which didn’t discuss Seralini’s paper, was ghostwritten by Monsanto.

The documents, posted last week by the law firm of Baum, Hedlund, Aristei and Goldman, show Monsanto engaged with a network of scientists and other commentators to spread the message that the Seralini paper was bad science and should be retracted. Seralini told Retraction Watch that this proves what he has been saying all along, that Monsanto led a concentrated effort to discredit his science and protect its bottom line. He said:

Continue reading Unearthed emails: Monsanto connected to campaign to retract GMO paper